U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07320625) titled 'Efficacy of Montelukast on STEMl Patients' on Dec. 22, 2025.
Brief Summary: Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial infarction (STEMI). Despite the continuous development of reperfusion therapy strategies in recent years, which have benefited countless STEMI patients, studies have shown that even when STEMI patients receive primary percutaneous coronary intervention (pPCI) within the therapeutic time window, the in-hospital mortality rate remains as ...